Vimarsana
Biggest News Aggregation in the World

Page 2 - Eric Ando News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric Ando. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Ando Today - Breaking & Trending Today

EVOX THERAPEUTICS LIMITED: Evox Therapeutics Appoints Peter Jones as Vice President of CMC - Vimarsana News

EVOX THERAPEUTICS LIMITED: Evox Therapeutics Appoints Peter Jones as Vice President of CMC

OXFORD, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice President

Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine - Vimarsana News

Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine

Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine - read this article along with other careers information, tips and advice on BioSpace

Excision BioTherapeutics Appoints Infectious Disease Expert - Vimarsana News

Excision BioTherapeutics Appoints Infectious Disease Expert

SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral...

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs Financing will support advancement of lead HIV potential cure program into clinical development - Vimarsana News

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs Financing will support advancement of lead HIV potential cure program into clinical development

Published: Feb 17, 2021 SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc. (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simple...